Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GE HealthCare Technologies (GEHC) EBITDA (2022 - 2026)

GE HealthCare Technologies filings provide 5 years of EBITDA readings, the most recent being $515.0 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 18.12% to $515.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.6 billion, a 2.39% decrease, with the full-year FY2025 number at $2.8 billion, up 5.26% from a year prior.
  • EBITDA hit $515.0 million in Q1 2026 for GE HealthCare Technologies, down from $827.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $827.0 million in Q4 2025 to a low of $509.0 million in Q1 2022.
  • Median EBITDA over the past 5 years was $629.0 million (2025), compared with a mean of $638.8 million.
  • Biggest five-year swings in EBITDA: grew 16.48% in 2025 and later decreased 18.12% in 2026.
  • GE HealthCare Technologies' EBITDA stood at $777.0 million in 2022, then fell by 11.33% to $689.0 million in 2023, then grew by 16.26% to $801.0 million in 2024, then grew by 3.25% to $827.0 million in 2025, then plummeted by 37.73% to $515.0 million in 2026.
  • The last three reported values for EBITDA were $515.0 million (Q1 2026), $827.0 million (Q4 2025), and $653.0 million (Q3 2025) per Business Quant data.